Aligos Therapeutics（NASDAQ:ALGS）报告季度每股亏损 $(13.08)，比分析师的共识预期 $(2.30) 差 468.7%。与去年同期每股亏损 $(5.50) 相比，这一数据下降了 137.82%。公司报告季度销售额为 62.9 万美元，超出分析师共识预期的 43.33 万美元 45.15%。与去年同期销售额 201 万美元相比，这一数据下降了 68.69%。

以上内容来自Benzinga Earnings专栏，原文如下：

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(13.08) per share which missed the analyst consensus estimate of $(2.30) by 468.7 percent. This is a 137.82 percent decrease over losses of $(5.50) per share from the same period last year. The company reported quarterly sales of $629.00 thousand which beat the analyst consensus estimate of $433.33 thousand by 45.15 percent. This is a 68.69 percent decrease over sales of $2.01 million the same period last year.